GlaxoSmithKline (GSK) and Will Biotechnology have signed a $ 1 billion contract with the U.S. government on the 17th for a new coronavirus drug, sotrovimab, that uses antibodies. Announced.
It is scheduled to be supplied by December 17, and additional purchases will be available in the United States until March 2022.
According to GSK, there are more than 750,000 supply contracts for sotrovimab worldwide. Includes 10,000 doses for Canada and up to 220,000 doses for the European Union (EU). The dose contracted with the United States has not been disclosed.
In the United States, emergency use of sotrovimab is approved for patients with mild to moderate coronavirus infection. The risk of hospitalization and death can be reduced by 79%.
James Saenz has over 14 years experience in the financial services industry giving him a vast understanding of how news affects the financial markets. He is an active day trader spending the majority of his time analyzing earnings reports and watching commodities and derivatives. James gives us an insight into the latest Analyst news hitting the business and financial markets in Wall Street.
Email: [email protected]analystsbuzz.com
Address: 16205 65th Avenue, Fresh Meadows, NY 11365 USA
Zip code: 11365